Abstracts included in the national Dutch influenza vaccination program, that encompasses the elderly of 65 years and older. The objective of this study is to estimate the cost and benefits of vaccinating healthy working adults aged 25 to 64 years against influenza. METHODS: Our cost-benefit analysis includes the direct and indirect costs associated with vaccination as well as the direct and indirect costs avoided by vaccination. The underlying model links influenza incidence to health-care resource use, work absenteeism and productivity loss. Health-care resource use was specified for general practitioner visits, hospitalizations and drugs. Clinical and economical parameter estimates were derived from published literature and Dutch registry data. 
Abstracts included in the national Dutch influenza vaccination program, that encompasses the elderly of 65 years and older. The objective of this study is to estimate the cost and benefits of vaccinating healthy working adults aged 25 to 64 years against influenza. METHODS: Our cost-benefit analysis includes the direct and indirect costs associated with vaccination as well as the direct and indirect costs avoided by vaccination. The underlying model links influenza incidence to health-care resource use, work absenteeism and productivity loss. Health-care resource use was specified for general practitioner visits, hospitalizations and drugs. Clinical and economical parameter estimates were derived from published literature and Dutch registry data. RESULTS: Vaccinating healthy working adults aged 25 to 44 years costs € 0,39 per person per year. Vaccinating persons aged 45 to 64 years saves € 1,51 per person per year. On the population level, vaccinating persons aged 25-44 years costs about € 1,4 million per year, vaccinating persons aged 45-64 years saves about € 2,3 million per year. On average, vaccinating healthy working adults saves € 0,9 million. The indirect costs prevented primarily determine the cost-benefit outcome of vaccination for healthy working adults. CONCLUSIONS: Influenza vaccination of healthy working adults is cost saving. These findings support routine vaccination for this group, from the employer's perspective. 
OBJECTIVES:
Toenail onychomycosis is the most common nail fungal infection. If left untreated, it can evolve into a more severe stage that can involve the matrix. The clinical management of patients remains constraining and long. In addition, relapses occur frequently after antifungal treatment. This has significant socio-economic impact. Combining topical and oral antifungals can increase cure rates and decrease treatment duration. The OnychoTree project aims at providing an evaluation tool to estimate economic consequences of the management of severe toenail onychomycosis in Europe.
METHODS:
The methodology for OnychoTree development follows a rigorous stepwise design to obtain an international model, valid for use across 17 countries: 1) an extensive literature review of international data on toenail onychomycosis; 2) the design of a core clinical management-decision tree; 3) the validation and completion of the core model (treatment patterns and medical resource use) by an expert panel of 12 dermatologists from six countries; 4) expansion and validation of the model to 11 additional countries through advisory panel interviews assessing national specificities (disease management and associated costs); 5) a meta-analysis of efficacy rates from relevant clinical trials of antifungals; 6) cost-effectiveness analyses. RESULTS: The initial common model was designed from the available international literature. The expert panel clinicians confirmed their interest for: 1) a clinical management model, and 2) cost-effectiveness evaluation including new combination therapies. They requested adaptations to reflect country-specific medical practice. After adaptation, they validated the core European pharmacoeconomic model. Advisory panel interviews confirmed these results, focusing on the need for countryspecific analyses based on a common decision tree. CONCLUSIONS: Cost-effectiveness analyses including the 17 country-specific data will be performed with the final model. These European results will make both medical professionals and the public aware of the possible improvement in health-care resource use for the management of severe toenail onychomycosis. 
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A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C
OBJECTIVE:
We conducted a cost-benefit analysis of two approaches to manage a regional outbreak of serogroup C meningococcal disease (MCD): 1. a planned mass immunization program (MIP) of 2,000,000 Quebec residents aged 2 months to 20 years, that would be implemented in September 2001; 2. an emergency MIP implemented at the peak of subsequent outbreaks. METHODS: As a reference case, we used the scenario that occurred in Quebec in 1991-several targeted regional vaccination programs were implemented in an attempt to ward off a more widespread outbreak of MCD. Unfortunately, at the end of 1992, public-health authorities had to implement a province-wide emergency MIP. We assessed the benefit of the programs using epidemiological data from the previous cycle of MCD in Quebec. Benefits included the number of new MCD cases prevented by the administration of Menjugate™ and their associated hospital and societal costs due to premature mortality and related morbidity. Costs included acquisition and administration cost of the conjugate vaccine, clerical, physician and health-services costs, and those related to lost productivity. We conducted the analysis in a societal perspective assuming Quebec would face a similar epidemiological situation in 2001 as the one that started in 1991. All costs were transformed into 2001 Canadian dollars at an annual inflation rate of 3%. RESULTS: Over a 12-month period, a planned MIP would prevent 127 new cases (18 deaths, 24 major complications) while saving $15.0 million in direct costs to
